Advertisement

Pharmaceutical Chemistry Journal

, Volume 49, Issue 4, pp 213–219 | Cite as

Selected Issues on Regulation of the Circulation of Non-Biological Complex Drugs

  • G. Ya. Shvarts
  • G. V. Ramenskaya
MOLECULAR-BIOLOGICAL PROBLEMS OF DRUG DESIGN AND MECHANISM OF DRUG ACTION

An analytical review of widely discussed issues on the classification of drugs based on the methods/sources of their preparation and the complexity of their structures is presented. According to the classification, drugs are divided into three types: (A) low-molecular-weight synthetic “conventional” drugs that are completely characterized chemically; (B) biological complex drugs that are not fully characterized chemically (BCD); and (C) non-biological/synthetic complex drugs that are not fully characterized chemically (NBCD). This classification has both scientific and practical significance due to the fact that NBCDs (liposomal drugs, complex iron—carbohydrate complexes, glatiramoids, low-molecular-weight heparins) are similar to BCDs with respect to both structure (a mixture of strongly bound macromolecular fragments not amenable to isolation and complete identification) and biological/pharmacological effects (immunogenicity, insufficient information about the mechanism of action). Recent practice shows that NBCD generic versions in addition to biosimilar drugs are actually not identical to the original drugs because of differences in the manufacturing technology. For this reason, the expedited review and registration of these drugs, which is analogous to that used for conventional low-molecular-weight drugs, seems to be insufficient.

Keywords

non-biological/synthetic drugs incompletely characterized chemical structure liposomal drugs iron–carbohydrate complexes glatiramoids review 

References

  1. 1.
    A. N. Mayeno, F. Lin, C. S. Foote, et al., Science, 250(4988), 1707 – 1708 (1990).CrossRefPubMedGoogle Scholar
  2. 2.
    E. Kh. Anaev and A. G. Chuchalin, Pul’monologiya, 4, 106 – 115 (2012).Google Scholar
  3. 3.
    J. Varga, J. Uitto, and S. A. Jimenez, Ann. Intern. Med., 116(2), 140 – 147 (1992).CrossRefPubMedGoogle Scholar
  4. 4.
    M. Wadhwa, A.-L. H. Skog, C. Bird, et al., Clin. Cancer Res., 5(6), 1353 – 1361 (1999).PubMedGoogle Scholar
  5. 5.
    A. V. Pivnik, V. N. Tonkoglaz, and D. V. Boiko, Klin. Med. (Moscow), 3, 55 – 59 (2006).Google Scholar
  6. 6.
    N. N. Spirin, D. S. Kasatkin, I. O. Stepanov, et al., Zh. Nevrol. Psikhiatr., 8, 27 – 33 (2012).Google Scholar
  7. 7.
    F. A. Khabirov, N. N. Babicheva, T. I. Khaibullin, et al., Zh. Nevrol. Psikhiatr., 9, 113 – 117 (2012).Google Scholar
  8. 8.
    US Food and Drug Administration; available from: www.fda.org.
  9. 9.
    Guideline on Similar Biological Medicinal Products, CHMP / 437 / 04, October 2005. European Medicines Agency; available from: http://www.ema.europa.eu/docs/enGB/documentlibrary/Scientificguideline/2009/09/WC500003517.pdf.
  10. 10.
    A. N. Vasil’ev, E. V. Gavrishina, R. R. Niyazov, et al., Remedium, 9(7 – 8), 49 – 54 (2013).Google Scholar
  11. 11.
    A. N. Mironov, D. V. Goryachev, I. A. Proskurina, and V. A. Merkulov, Vedomosti HTsESMP, 3, 3 – 8 (2014).Google Scholar
  12. 12.
    Yu. B. Belousov, S. K. Zyryanova, and M. V. Davydovskaya, Zh. Nevrol. Psikhiatr., 9(2), 19 – 24 (2011).Google Scholar
  13. 13.
  14. 14.
    J. M. Nicholas, GaBi J., 3(2), 71 – 78 (2014).CrossRefGoogle Scholar
  15. 15.
    D. J. A. Crommelin, J. S. B. De Vlieger, V. Weinstein, et al., AAPS J., 16(1), 11 – 14 (2014).PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    D. S. Watson, A. N. Endsley, and L. Huang, Vaccine, 30(13), 2256 – 2272 (2012).PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    A. Yu. Baryshnikov, Vestn. Ross. Akad. Med. Nauk, 3, 23 – 31 (2012).PubMedGoogle Scholar
  18. 18.
    A. Gabizon, H. Sheemda, and Y. Barenholz, Clin. Pharmacokinet., 42(5), 419 – 436 (2003).CrossRefPubMedGoogle Scholar
  19. 19.
    J. E. Toblli, G. Cao, L. Oliveri, and M. Angerosa, Arzneim. Forsch., 59(4), 176 – 190 (2009).Google Scholar
  20. 20.
    C. Holloway, J. Mueller-Berghaus, B. S. Lima, et al., Ann. N. Y. Acad. Sci., 1276, 26 – 36 (2012).CrossRefPubMedGoogle Scholar
  21. 21.
    J. M. Nicholas, GaBi J., 3(2), 71 – 78 (2014).CrossRefGoogle Scholar
  22. 22.
    M. J. Helenek, M. L. Tokars, and R. P. Lawrence, US Pat. Appl. No. 20130230565 / A1, Sept. 5, 2013; “Methods and compositions for administration of iron.”Google Scholar
  23. 23.
    V. Yu. Shilo and N. N. Khasabov, Lech. Vrach, No. 1, 25 – 31 (2008).Google Scholar
  24. 24.
    A. B. Pai, A. V. Boyd, C. R. McQuade, et al., Pharmacotherapy, 27(3), 343 – 350 (2007).CrossRefPubMedGoogle Scholar
  25. 25.
    European Medicines Agency. Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications. EMA / CHMP / SWP / 100094 / 2011.17March2011 [homepage on the internet]. 2011 Apr [cited 2014 Feb 24]. Available from: http://www.ema.europa.eu/docs/enGB/documentlibrary/Scientificguideline/2011/04/WC500105048.pdf.
  26. 26.
    E. S. Lee, B. R. Park, J. S. Kim, et al., Curr. Med. Res. Opin., 29(2), 141 – 147 (2013).CrossRefPubMedGoogle Scholar
  27. 27.
    J. Rottembourg, A. Kadri, E. Leonard, et al., Nephrol., Dial., Transplant., 26(10), 3262 – 3267 (2011).CrossRefGoogle Scholar
  28. 28.
    L. S. Scott, CNS Drugs, 27, 971 – 988 (2013).CrossRefPubMedGoogle Scholar
  29. 29.
    J. Conner, J. Autoimmun. Cell Resp., 1:3, (2014); 1DOI: http://dx.doi.org/ 10.7243/2054–989X-1–3.
  30. 30.
    H. Varcony, V. Weinstein, E. Klinger, et al., Pharmacotherapy, 10(4), 657 – 668 (2009).Google Scholar
  31. 31.
    T. Ziemssen and W. Schrempf, Int. Rev. Neurobiol., 79, 537 – 570 (2007).CrossRefPubMedGoogle Scholar
  32. 32.
    M. Sela and M. R. Hillerman, Proc. Natl. Acad. Sci. USA, 101, Suppl. 2, 14559 (2004).PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    C. Ford, A. D. Goodman, K. Johnson, et al., Mult. Scler., 16, 342 – 350 (2010).PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    S. Bakshi, V. Chalifa-Caspi, I. Plaschkes, et al., Expert Opin. Ther. Targets, 17(4), 351 – 362 (2013).CrossRefPubMedGoogle Scholar
  35. 35.
    O. Khan, P. Rieckman, A. Boiko, et al., Ann. Neurol., 73, 705 – 713 (2013).CrossRefPubMedGoogle Scholar
  36. 36.
  37. 37.
    E. Klinger, Eurasian Pat. No. 019998 B1 (2014), publ. date Jul. 30, 2014.Google Scholar
  38. 38.
    Momenta. [press release]. Cambridge, MA. 2008 Jul 11 [cited 2014 Feb 24]. Available from: http://ir.momentapharma.com/releasedetail.cfm’ReleaseID=320978.
  39. 39.
  40. 40.
  41. 41.
    G. Ya. Shvarts and G. V. Ramenskaya, Khim.-farm. Zh., 46(11), 29 – 34 (2012); Pharm. Chem. J., 46(11), 656 – 660 (2012).Google Scholar
  42. 42.
    F. Towfic, J. M. Funt, K. D. Flower, et al., PLoS One, 9:e83757. doi: 10.1371 / journal.pone.0083757 (2014).PubMedCentralCrossRefPubMedGoogle Scholar
  43. 43.
    Y. Ramot, M. Rosenstock, E. Klinger, et al., Toxicol. Pathol., 40(1), 40 – 54 (2012).CrossRefPubMedGoogle Scholar
  44. 44.

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • G. Ya. Shvarts
    • 1
    • 2
  • G. V. Ramenskaya
    • 1
  1. 1.I. M. Sechenov First Moscow State Medical UniversityMoscowRussia
  2. 2.Teva LLCMoscowRussia

Personalised recommendations